Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 4Prostatic Neoplasms 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Glioblastoma 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

pembrolizumab 26Nivolumab 10Cisplatin 9Gemcitabine 8Docetaxel 6enfortumab vedotin 5atezolizumab 5Ipilimumab 5Carboplatin 5sacituzumab govitecan 4Paclitaxel 4Pemetrexed 3Cyclophosphamide 3vofatamab 2tremelimumab 2tislelizumab 2regorafenib 2lenvatinib 2epacadostat 2durvalumab 2avelumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Leucovorin 2Biopsy 2Bevacizumab 2B701 protein, Human herpesvirus 6 2ALT-803 2yeast-CEA vaccine 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Transitional Cell × rucaparib × Clear all
NCT03992131 2024-01-16

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

pharmaand GmbH

Phase 1/2 Terminated
25 enrolled 11 charts
BreastGenitourinaryGynecologic

Carcinoma, Transitional Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡